
1. sci rep. 2016 nov 14;6:36921. doi: 10.1038/srep36921.

inhibition jcpyv infection mediated targeted viral genome editing using
crispr/cas9.

chou yy(1), krupp a(2), kaynor c(2), gaudin r(1), m(1), cahir-mcfarland e(2), 
kirchhausen t(1)(3).

author information: 
(1)department cell biology, harvard medical school, program cellular
and molecular medicine, boston children's hospital, boston, 02115, usa.
(2)department neuroimmunology, biogen, cambridge, 02142, usa.
(3)department pediatrics, harvard medical school, boston, 02115, usa.

progressive multifocal leukoencephalopathy (pml) debilitating disease
resulting infection oligodendrocytes jc polyomavirus (jcpyv).
currently, anti-viral therapeutic available jcpyv infection. 
the clustered regularly interspaced short palindromic repeat
(crispr)/crispr-associated protein 9 (cas9) system (crispr/cas9) genome
editing tool capable introducing sequence specific breaks double stranded
dna. show crispr/cas9 system restrict jcpyv life cycle
in cultured cells. utilized crispr/cas9 target noncoding control region
and late gene open reading frame jcpyv genome. found significant
inhibition virus replication viral protein expression cells recipient
of cas9 together jcpyv-specific single-guide rna delivered prior after
jcpyv infection.

doi: 10.1038/srep36921 
pmcid: pmc5107994
pmid: 27841295  [indexed medline]

conflict interest statement: work partially funded biogen. a.k.,
c.k., e.cm., receive compensation members biogen stocks the
company. y.c., m.m., r.g., t.k., declare potential conflict interest.

